PLATELET-ACTIVATING FACTOR-INDUCED ISCHEMIC BOWEL NECROSIS - AN INVESTIGATION OF SECONDARY MEDIATORS IN ITS PATHOGENESIS
- 1 February 1986
- journal article
- research article
- Vol. 122 (2) , 231-239
Abstract
The authors have previously reported a model of ischemic bowel necrosis produced in the rat by synthetic platelet-activating factor (PAF) or a combination of PAF and bacterial endotoxin. Because rat platelets are refractory to PAF and thromboemboli were not found in the mesenteric or intestinal microvasculature, they suspected that secondary mediators were involved in the pathogenesis of bowel necrosis. They have found the following (1) lipoxygenase products of arachidonic acid, especially leukotrienes (LT), probably played an important role in the pathogenesis of bowel necrosis, because diethylcarbamazine (an inhibitor for LTA synthesis) and FPL55712 (LT antagonist) ameliorated, and at times completely prevented, the lesions. NDGA (a nonspecific lipoxygenase inhibitor) was less effective, probably because of its additional effect on cyclooxygenase inhibition. (2) Verapamil, a calcium channel blocker, ameliorated the disease. (3) Thromboxane A2, a potent vasoconstrictor, was probably not responsible for the ischemia of the gastrointestinal tract. This is suggested by the ineffectiveness of OKY-046 in preventing bowel necrosis. (4) Prostaglandin (PG) E1 infusion often prevented the bowel necrosis, which suggested beneficial effects of vasodilating PGs, probably released as a defense mechanisms. (5) Indomethacin aggravated the disease, probably by inhibiting PG release and shifting the metabolic pathway toward the lipoxygenase pathway. (6) Antihistamine and antiserotonin had no effect, which suggested that these mediators were not involved in the pathogenesis of bowel necrosis. (7) Shock produced by PAF was probably not the only cause of bowel necrosis, because reversal of the hypotension did not always prevent the development of bowel necrosis. (8) Hemoconcentration (increased vasopermeability) and leukopenia induced by PAF did not correlate with the development or severity of bowel necrosis.This publication has 27 references indexed in Scilit:
- Release and vasoconstictor effect of leukotriene C4-like immunoreactive material in the anaphylactic guinea-pig mesenteric vascular bedEuropean Journal of Pharmacology, 1984
- Synthesis and degradation of prostaglandin e2 in the epithelial and sub-epithelial layers of the rat intestineBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1982
- Generation of leukotrienes by purified human lung mast cells.Journal of Clinical Investigation, 1982
- Generation of leukotriene C4 from a subclass of mast cells differentiated in vitro from mouse bone marrow.Proceedings of the National Academy of Sciences, 1982
- Inhibition of leukotriene biosynthesis in mastocytoma cells by diethylcarbamazineBiochemical Pharmacology, 1982
- BACKGROUND AND PRESENT STATUS OF RESEARCH ON PLATELET‐ACTIVATING FACTOR (PAF‐ACETHER)Annals of the New York Academy of Sciences, 1981
- Clostridia colonization and clostridial toxin in neonatal necrotizing enterocolitisThe Journal of Pediatrics, 1981
- Platelet-activating factor (PAF-acether) and macrophagesCellular Immunology, 1981
- Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivativesEuropean Journal of Pharmacology, 1980
- PATHOGENESIS OF ENTERITIS NECROTICANS IN PAPUA NEW GUINEAThe Lancet, 1976